A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS) compared to placebo in participants with symptomatic kneE osteoarthritis (OA) and dysLipidemia (MaRVeL Study)
https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12621000654853
- Forums
- ASX - By Stock
- General OA media and info
A Double-Blind, RandoMised, Placebo-Controlled Study to Assess...
-
- There are more pages in this discussion • 452 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M |
Open | High | Low | Value | Volume |
23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 33682 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.235 |
2 | 44021 | 0.230 |
1 | 100000 | 0.225 |
5 | 234973 | 0.220 |
4 | 96293 | 0.215 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 33682 | 3 |
0.250 | 59284 | 5 |
0.255 | 21666 | 2 |
0.260 | 41294 | 6 |
0.265 | 37500 | 2 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online